Cargando…

Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance

SIMPLE SUMMARY: Prostate cancer is the most common malignancy in men, with a high mortality rate when disease progresses to metastasis and therapeutic resistance. Evidence implicates inflammation as a driver of prostate cancer risk and has a significant impact on processes in the tumor microenvironm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Archer, Maddison, Dogra, Navneet, Kyprianou, Natasha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602551/ https://www.ncbi.nlm.nih.gov/pubmed/33076397 http://dx.doi.org/10.3390/cancers12102984

Ejemplares similares

Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer
por: Kahn, Barbara, et al.
Publicado: (2014)

Exosomes as A Next-Generation Diagnostic and Therapeutic Tool in Prostate Cancer
por: Gaglani, Simita, et al.
Publicado: (2021)

Profiling Prostate Cancer Therapeutic Resistance
por: Wade, Cameron A., et al.
Publicado: (2018)

Inflammation in prostate cancer progression and therapeutic targeting
por: Stark, Timothy, et al.
Publicado: (2015)

Homeless Cells Escape Death and Deliver Lethal Cancer
por: Archer, Maddison, et al.
Publicado: (2021)

Circadian Rhythm Disruption as a Contributor to Racial Disparities in Prostate Cancer
por: Dasari, Sonali S., et al.
Publicado: (2022)

Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance
por: Altschuler, Joshua, et al.
Publicado: (2021)

COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer
por: Mihalopoulos, Meredith, et al.
Publicado: (2020)

Clinical Significance of Extracellular Vesicles in Prostate and Renal Cancer
por: Chen, Tzu-Yi, et al.
Publicado: (2023)

Impact of Circadian Rhythms on the Development and Clinical Management of Genitourinary Cancers
por: Kaur, Priya, et al.
Publicado: (2022)

Mechanisms navigating the TGF-β pathway in prostate cancer
por: Cao, Zheng, et al.
Publicado: (2015)

Deciphering Evolutionary Dynamics and Lineage Plasticity in Aggressive Prostate Cancer
por: Kyprianou, Natasha, et al.
Publicado: (2021)

Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression
por: Grant, Campbell M., et al.
Publicado: (2013)

Biological Mechanisms and Therapeutic Opportunities in Mammographic Density and Breast Cancer Risk
por: Archer, Maddison, et al.
Publicado: (2021)

Prostate tumor neuroendocrine differentiation via EMT: The road less traveled
por: Dicken, Haley, et al.
Publicado: (2019)

The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone
por: Göbel, Andy, et al.
Publicado: (2021)

Drivers of Radioresistance in Prostate Cancer
por: King, Liam, et al.
Publicado: (2022)

Nuclear spindles pave the way to metastasis
por: Hensley, Patrick J., et al.
Publicado: (2017)

A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review)
por: LACY, JOHN M., et al.
Publicado: (2014)

Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer
por: Chakraborty, Goutam, et al.
Publicado: (2023)

Targeting Oncoimmune Drivers of Cancer Metastasis
por: Kudo-Saito, Chie, et al.
Publicado: (2021)

Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis
por: Harris, Koran S., et al.
Publicado: (2017)

Anoikis in phenotypic reprogramming of the prostate tumor microenvironment
por: Nepali, Prerna R., et al.
Publicado: (2023)

Targeting Cancer Stem Cells as the Key Driver of Carcinogenesis and Therapeutic Resistance
por: Eid, Refaat A., et al.
Publicado: (2023)

The Promise of Novel Molecular Markers in Bladder Cancer
por: Miremami, Jahan, et al.
Publicado: (2014)

Emerging biomarkers of prostate cancer (Review)
por: MARTIN, SARAH K., et al.
Publicado: (2012)

The Resilient Child: Sex-Steroid Hormones and COVID-19 Incidence in Pediatric Patients
por: Mihalopoulos, Meredith, et al.
Publicado: (2020)

Wound Healing and Cancer Stem Cells: Inflammation as a Driver of Treatment Resistance in Breast Cancer
por: Arnold, Kimberly M, et al.
Publicado: (2015)

Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis
por: Yan, Yiwu, et al.
Publicado: (2022)

Cancer-derived extracellular succinate: a driver of cancer metastasis
por: Kuo, Cheng-Chin, et al.
Publicado: (2022)

CD44: A metastasis driver and therapeutic target
por: Sottnik, Joseph L., et al.
Publicado: (2016)

Cancer Stemness/Epithelial–Mesenchymal Transition Axis Influences Metastasis and Castration Resistance in Prostate Cancer: Potential Therapeutic Target
por: Castellón, Enrique A., et al.
Publicado: (2022)

Macrophages as Key Drivers of Cancer Progression and Metastasis
por: Nielsen, Sebastian R., et al.
Publicado: (2017)

RET signaling in breast cancer therapeutic resistance and metastasis
por: Pecar, Geoffrey, et al.
Publicado: (2023)

Transcription Factors as Novel Therapeutic Targets and Drivers of Prostate Cancer Progression
por: Xie, Kangzhe, et al.
Publicado: (2022)

Editorial: Molecular drivers of prostate cancer pathogenesis and therapy resistance
por: Patel, Girijesh Kumar, et al.
Publicado: (2023)

Reduced Arginyltransferase 1 is a driver and a potential prognostic indicator of prostate cancer metastasis
por: Birnbaum, Michael D., et al.
Publicado: (2018)

Reactive oxygen species: a volatile driver of field cancerization and metastasis
por: Liao, Zehuan, et al.
Publicado: (2019)

Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells
por: Cao, Zheng, et al.
Publicado: (2017)

Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance
por: Huang, Phoebe A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_is4dl2ckdr2k2mfmviplllrfte